According to a new market research report published by Global Market
Estimates, the Global Adeno-Associated Viral Vector Manufacturing Market
is projected to grow at a CAGR value of 22.9% from 2022 and 2027.
Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Global Adeno-Associated Viral Vector Manufacturing Market - Forecast to 2027" https://www.globalmarketestimates.com/market-report/adeno-associated-viral-vector-manufacturing-market-3736
Biomarin Pharmaceutical, Sarepta Therapeutics, Roche (Spark Therapeutics), Sangamo, Pfizer, NightstaRx, Freeline Therapeutics, Horama S.A, MeiraGTx, RegenxBio, Asklepios Biopharmaceutical, and Audentes Therapeutics, among others, are the key players in the adeno-associated viral vector manufacturing market.
Type Outlook (Revenue, USD Million, 2022-2027)
· Single-stranded AAV (ssAAV)
· Self-complementary AAV (scAAV)
Application Outlook (Revenue, USD Million, 2022-2027)
· Lysosomal Storage Disorders
· Neurological Disorders
Regional Outlook (Revenue, USD Million, 2022-2027)
- The U.S.
- Rest of Europe
- South Korea
- Rest of APAC
Central & South America
- Rest of CSA
Middle East & Africa
- Saudi Arabia
- Rest of MEA
Contact: Yash Jain
Email address: firstname.lastname@example.org
Phone Number: +16026667238